It's one of the most common questions men quietly type into search engines: can the same medications helping them lose weight also improve their erections? The answer, based on a growing body of research, is more encouraging than most men expect.
What the Research Actually Shows
A 2025 review examining men with type 2 diabetes and obesity found that GLP-1 receptor agonists improved erectile function, likely by restoring the metabolic and vascular balance essential for the male sexual response. One year-long study showed that combining metformin with liraglutide or dulaglutide significantly improved International Index of Erectile Function (IIEF) scores, especially in men who lost more weight or had baseline vascular impairment.
A 2026 paper published in the International Journal of Impotence Research further outlined how GLP-1 medications translate cardiometabolic benefits into erectile outcomes. The connection is straightforward: obesity and insulin resistance damage blood vessels, reduce nitric oxide, and fuel chronic inflammation—all of which impair the vascular mechanics of erection. GLP-1s attack these root causes.
The Testosterone Connection
Erectile dysfunction and low testosterone frequently coexist, and obesity is the common thread. Data presented at ENDO 2025 showed that 18 months of GLP-1 therapy raised testosterone normalization rates from 53% to 77% in men with obesity—without any exogenous testosterone. Total testosterone levels rose from a mean of 320 ng/dL to 368 ng/dL.
Unlike testosterone replacement therapy, which suppresses the body's own hormone production, GLP-1 medications appear to restore natural hypothalamic-pituitary-gonadal (HPG) axis function. One researcher at ENDO 2025 noted that tirzepatide "appears to restore axis function," offering an alternative that "addresses root metabolic causes rather than symptomatically replacing testosterone."
The Caveats
Not all findings are uniformly positive. A 2025 TriNetX database study found that prescribing semaglutide for weight loss in non-diabetic, obese patients was associated with an increased risk of ED diagnosis. However, researchers noted this could reflect detection bias—men engaging with the healthcare system for weight loss may be more likely to report and receive treatment for ED than those not seeking care.
A separate 2026 review also noted that GLP-1 medications may decrease sexual desire through centrally mediated mechanisms that reduce hedonic drive—the same pathway that reduces food cravings may also dampen libido in some patients.
Who Benefits Most
The clearest evidence for GLP-1-related ED improvement is in men who have obesity, insulin resistance, or type 2 diabetes as contributing factors. If excess weight is driving your ED—and for many men over 40, it is—addressing the weight can improve vascular function, testosterone levels, and erectile quality simultaneously.
For men whose ED has other primary causes (anxiety, medication side effects, Peyronie's disease, nerve damage), GLP-1 therapy alone is unlikely to resolve the issue. PDE5 inhibitors remain the first-line pharmacologic treatment for ED regardless of cause.
Treatment Options
Men dealing with both weight and ED can now address both through a single telehealth platform:
Compounded medications are not FDA-approved. FDA does not evaluate compounded products for safety, effectiveness, or quality.
Compounded medications are not FDA-approved. FDA does not evaluate compounded products for safety, effectiveness, or quality.
The Bottom Line
GLP-1 medications aren't ED drugs. But for men whose erectile dysfunction is rooted in metabolic dysfunction—obesity, insulin resistance, vascular inflammation—the weight loss and metabolic improvement from GLP-1 therapy can produce meaningful improvements in sexual function. The research is early but directionally encouraging, and the dual benefit of losing weight while improving erectile health makes these medications worth discussing with a provider.